Business Description
Founded in 1996 and headquartered in Siena, Italy, Philogen is a biotechnology company focused on developing targeted treatments for cancer and chronic inflammatory conditions, with operations across Switzerland and the European Union. The company has built a broad pipeline of antibody-based therapies and small molecule drug candidates, several of which are currently being evaluated in late-stage clinical trials for conditions such as melanoma, soft tissue sarcoma, and lung cancer. Philogen is also advancing earlier-stage programs aimed at diagnosing and treating a range of solid tumors, including prostate cancer and kidney cancer, using highly precise molecular targeting technology.
